B Cell
FDA grants fast track, RMAT designations to CAR-T for advanced non-Hodgkin lymphoma
The FDA granted fast track and regenerative medicine advanced therapy designations to CB-010, a chimeric antigen receptor T-cell therapy, for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma.
Inebilizumab reduces B-cell subsets in neuromyelitis optica spectrum disorder attacks
Treatment with inebilizumab was associated with reduction in aquaporin-4 antibody titers and B cells for those with neuromyelitis optica spectrum disorder, according to an expert at ECTRIMS 2022.
VIDEO: Natural killer cell therapies for B-cell lymphoma perform "surprisingly well"
In this video, Joshua Sasine, MD, PhD, discusses a set of abstracts presented at ASH that evaluated natural killer cell therapies such as FT596 and FT516 in patients with relapsed/refractory B-cell lymphoma.
B-cell therapies, mycophenolate worsen COVID-19 vaccine response in inflammatory disease
Patients with chronic inflammatory disease on immunosuppressants, especially B-cell depleting agents, mycophenolate and glucocorticoids, exhibited poor antibody responses to the mRNA vaccine for COVID-19, according to a presenter here.